Autoi u it appea s to o t i ute sig ifi a tl to a diffe e t heu atologi diseases, i ludi g heu atoid a th itis RA , s ste i lupus e the atosus SLE , de ato ositis, Sjög e s d o e, s ste i s le osis a d the a ti eut ophil toplas i a ti od ANCAasso iated as ulitides. The est e ide e fo autoi u it is the p ese e of autoa ti odies i a la ge p opo tio of patie ts. These autoa ti odies a e lass -s it hed, so ati all utated, ofte high affi it a d di e ted agai st di e se epitopes o the autoa tige s -all featu es asso iated ith T ell depe de t i u e espo se. The e a e also data, pa ti ula l i SLE, de o st ati g the p ese e of autoa ti odies, a d he e autoi u it , ea s efo e the o set of li i al disease. The p ese t pa adig fo the de elop e t of these autoi u e diseases is that autoi u it de elops i fou stages: ge eti p edispositio , i itiatio , pe petuatio a d p og essio a d li i al disease. B ells take up a d p ese t autoa tige s ia spe ifi ell su fa e i u oglo uli s to T ells a d the a help egulate a d o ga ize i fla ato espo ses. The i po ta e of these latte fu tio s has ee de o st ated i u i e SLE, he e B ells ha e ee fou d to e iti al to the de elop e t of disease e e he the a e u a le to se ete autoa ti odies.
The u de sta di g of i u opathoge i e ha is s i autoi u e disease i ludi g SLE has i eased e po e tiall a d this has led to the dis o e of o el ta gets fo hi h iologi o ta geted the apies ha e ee de eloped agai st. The ai sta of the ap fo se e e a ifestatio s of SLE i lude the use of high-dose o ti oste oids a d toto i age ts su h as lophospha ide CYC hi h ha e ee asso iated ith a i eased isk of se ious a d oppo tu isti i fe tio s. Si e the s, e ha e a gued fo o e judi ious use of ste oids a d o e e e tl , o t olled studies ha e de o st ated that lo -dose i. . CYC a d ophe olate ofetil a e e uall effe ti e a d less to i tha high dose CYC i the t eat e t of lupus eph itis.
The pote tial ad a tage of iologi the ap is possi l , a ette safet p ofile ith less ge e al i u osupp essio . These ta geted the apies a a ge f o s all ole ules that spe ifi all i hi it i fla ato p o esses at a i t a ellula , ell-ell o ell-at i le el to o o lo al a ti odies A , solu le e epto s o atu al a tago ists that i te fe e ith toki e fu tio , ellula a ti atio a d i fla ato ge e t a s iptio .
The i u opathoge i hall a k of SLE is the pol lo al B ell a ti atio hi h leads to h pe glo uli e ia, autoa ti od p odu tio a d i u e o ple fo atio Figu e . The fu da e tal a o alit appea s to e the failu e of T ells to supp ess the fo idde B ell lo es due to ge e alized T ell d s egulatio ith esulta ts e ess i CD + T ell a ti it a d defi ie t CD + toto i /supp esso fu tio . I additio , B a d T-ell i te a tio is fa ilitated se e al toki es su h as IL-as ell as o-sti ulato ole ules su h as CD /CD L, B /CD /CTLA-hi h i itiate the se o d sig al. These i te a tio s togethe ith i pai ed phago ti lea a e of i u e o ple es a d apoptoti ate ial pe petuate the i u e espo se ith esulta t tissue i ju .
Figure . I u opathoge esis of SLE adapted fro Moc CC et al.
The p otot pi iologi age ts fi st app o ed fo use i heu ati disease e e the a titu ou e osis fa to TNF-ά i hi ito s: eta e ept a d i fli i a , fo the t eat e t of heu atoid a th itis. Si e the i itial su ess, its use has ee e te ded to the t eat e t of spo d loa th opath a k losi g spo d litis, pso iati a th itis a d so e p eli i a data has e e ged suggesti g e efit i othe heu ati diseases su h as se e al fo s of s ste i as ulitis Beh et's disease. Chu g -St auss s d o e, a d pol a te itis odosa a d e e a e tai su g oup of patie ts ith SLE. Follo i g this lead, a e ge e atio of iologi age ts fo the t eat e t of SLE is u e tl ei g de eloped, so e of hi h ha e ea hed li i al phase t ials. The follo i g dis ussio o these o el the apies ha e ee lassified a o di g to the pote tial ta gets of the i u e as ade i SLE.
. B ell targeted therapies
It is o lea that apa t f o autoa ti od p odu tio , B ells pla a iti al ole i a plif i g the i u e espo se th ough its fu tio as a tige -p ese ti g ells. Autoa tige s a e p ese ted ia spe ifi ell su fa e i u oglo uli s to T ells togethe ith a se o d sig al ia o sti ulato ole ules hi h leads to T ell a ti atio . B ell lo kade Figu e a thus e di e ted at: B ell su fa e e epto s CD-, CD-. i hi itio of o-sti ulato sig als CTLA Ig, i hi itio of B ell su i al a tiBL S . a d i du tio of B ell a e g B ell tole age s .
. . Blo kade of B-ell surfa e re eptors
Ritu i a , a o o lo al a ti od agai st CD-+ B ells as fi st app o ed fo use i the t eat e t of o -Hodgki 's ell l pho a. It sele ti el depletes i atu e, atu e, ai e a d e o B ells. Plas a ells do ot e p ess CD-a d a e he e u affe ted. The e is e ou agi g data f o ope la el t ials a d ase epo ts de o st ati g its effi a a d safet i SLE. Nota l , it appea s to e e efi ial i those ith a ti e ef a to disease a d o e of the studies thus fa ha e epo ted sig ifi a t ad e se effe ts, pa ti ula l that of se ious i fe tio . This o se atio has also ee suppo ted othe e e t ase epo ts iti g su essful out o es i patie ts ith life-th eate i g SLE e al, hae atologi al a d e t al e ous s ste i ol e e t . It appea s, f o the studies pe fo ed, that su essful depleto s patie ts ith < % B ells i pe iphe al lood ha e a o e sustai ed li i al espo se o pa ed to "poo depleto s" a d this a ia le espo se a e elated to pol o phis s of FC γ e epto s as ell as the dose of itu i a .
. . I hi itio of osti ulatory sig als
Cell su fa e ole ules that ediate ell-ell i te a tio a d ge e ate i t a ellula io he i al sig als i the i te a ti g ells a e te ed osti ulato ole ules . These p o ide the u h eeded se o d sig al fo T ell a ti atio a tige -p ese ti g ells Figu e . The osti ulato ta gets that ha e ee o a e u de goi g e aluatio i patie ts ith SLE i lude the CD -CD L a d CD -CTLA -B ole ules. CTLA toto i T-l pho te a tige , e p essed o a ti ated T ell su fa es, p o ides i hi ito sig als ith do egulate T ell fu tio he eas CD -B i te a tio p o otes T-ell a ti atio . As the fo e has highe affi it to B , i estigato s ha e de eloped CTLA Ig, a solu le e epto fusio p otei of the e t a ellula do ai of CTLA a d F po tio of IgGI to lo k CD -B i te a tio a d su se ue t T ell depe de t B ell fu tio . Follo i g p o isi g a i al date de o st ati g i p o e e t i lupus eph itis, su i al a d edu tio i autoa ti od a d toki e IL-, a d p odu tio ith CTLA g o othe ap as ell as i o i atio ith CYC a d e ou agi g esults i patie ts ith heu atoid a th itis, a Phase I/II stud i SLE patie ts o du ted NIAID is u de a .
Figure . Targets for SLE therapy adapted fro Vasoo a d GRV Hughes
U fo tu atel , the a ti-CD L A t eat e t app oa h i hu a lupus as ot f uitful, as sho t-te ad i ist atio of the a ti-CD L A , uplizu a i lupus eph itis as asso iated ith life-th eate i g p oth o oti a ti it despite i itial e ou agi g data i the se olog a d e al fu tio of the patie ts. I o i all , t eat e t ith a othe a ti-CD L A desig ated as IDECdid ot p o e to e li i all effe ti e i hu a , SLE, despite ei g ell tole ated. A gli pse of othe pote tial ta gets i lude o o lo al a ti odies agai st CD osti ulato ole ules o T ells i NZB/WF SLE-p o e i e hi h ha e e e sed the p og essio of esta lished SLE-like disease a d p olo ged su i al.
. . I hi itio of B ell survival
B-l pho te sti ulato BL S also k o as BAFF, is a e e of the TNF fa il of toki es. E p essio of BL S e epto s BCMA, TACI, BAFFR is la gel est i ted to B ells. It has ee sho i a i al odels that o e e p essio of BL S esults i a lupus-like state a d k o k-out i e odels fo BL S a elio ates the disease. I hu a SLE, o e e p essio of BL S is o o pe siste t ele atio i up to % of patie ts o e a o e ea follo -up pe iod . The esults of a e e t Phase I t ial of full hu a ized o o lo al IgG a ti od agai st BL S e e e ou agi g. The e as a sig ifi a t de ease i pe iphe al B-ells a d t eat e t as a sig ifi a t de ease i pe iphe al B-ells a d t eat e t as ell tole ated ith o se ious ad e se ea tio s. Ho e e , o li i al o se ologi al i p o e e t as dete ted i this oho t stud . Cu e tl , a Phase II li i al t ial is o goi g a d othe BL S a tago ists a e ei g e plo ed fo use i hu a s. The i lude BAFFR-Ig p e li i al t ials a d TACI-Ig Phase I i o al su je ts .
. . I du tio of B ell a ergy
The i t odu tio of s theti ole ules hi h ha e the a ilit to ossli k ith a tidsDNA a ti odies o the su fa e of B ells leadi g to a e g o apoptosis is a othe o el the apeuti app oa h that is u de goi g fu the e aluatio i hu a SLE. LJP is o e su h age t, o posed of fou deo u leotide se ue es ou d to a t ieth le e gl ol a k o e that has sho p o isi g esults i the Phase II/III li i al t ials. The t o la ge a do ized, DBPC studies i patie ts ith lupus eph itis sho ed that the e as a sig ifi a t dela i the ti e a d i ide e of e al fla es, as ell as edu tio i a ti-dsDNA A le els i the su g oup that de o st ated high affi it i di g of a ti ds-DNA to LJP ould e useful adju t to u e t the apies fo lupus eph itis ut the e ui e e t fo it to e ad i iste ed eekl a li it its utilit . The e uit e t fo the Phase IV DBRCT e aluati g high dose LJP g a d g i patie ts ith a ti e lupus eph itis is o goi g. A si ila app oa h is also ei g i estigated fo the t eat e t of a tiphospholipid s d o e usi g LJP .
. Co ple e t i a tivatio
I SLE, o ple e t a ti atio follo s i u e o ple fo atio a d the fo al poi t o the fi al o o path a is C ith esulta t fo atio of the e a e atta k o ple MAC C -that auses tissue da age. The lo kade of C i SLE as fi st studied i u i e lupus hi h sho ed sig ifi a t a elio atio of e al disease a d a ked i ease i su i al. A Phase I li i al t ial of a ti C A e ealed that it as safe a d ell tole ated ith a t e d to i p o e e t i disease assess e t s o es i the high dose g oup g/kg .
. Cytoki e odulatio C toki es a e lo ole ula eight ediato s of ell-ell o u i atio a d i lude i te leuki s ILs , i te fe o s IFNs , g o th fa to s a d othe s. The a e hete oge eous a d fu tio i a o e lappi g a e . The ke p i iple is that the et iologi espo se i a tissue is the esult of ala e et ee lo al le els of p oi fla ato o a ti-i fla ato toki es. SLE is o side ed so e to e a Th-d i e disease ith do u e ted ele atio s i se u IL-, , .
. . A ti -IL A
I te leuki -ILle els a e ele ated i patie ts ith a ti e SLE a d o elate ith disease a ti it . These alte atio s i IL a d TGF eta egulatio appea to esult i T-ell d sfu tio a ele ated T -ell apoptosis a d d s egulatio of T-ell depe de t B-ell fu tio . The esults of a pilot stud of si patie ts ith a ti e SLE t eated ith a ti IL-A fo th ee eeks a d follo ed up fo a pe iod of si o ths e e p o isi g. The e as a ked edu tio i i ulati g IL le els ith o espo di g li i al i p o e e t de li e i MEX-SLEDAI a d ea dail p ed isolo e dose hi h e e a i al at t o o ths a d sustai ed at the e d of the si o th e ie . Apa t f o o e ase of ild t a sfusio ea tio , o se ious ad e se e e ts e e epo ted.
. . A ti IL6 A
I te leuki -IL-le els a e ele ated i oth hu a a d u i e s ste i lupus e the atosus SLE . IL-is a pote t p oi fla ato toki e that has a ide a ge of iologi al a ti ities i ludi g te i al diffe e tiatio of B -l pho tes i to a ti odfo i g ells a d T ells to effe to ells. IL-lo kade a elio ates disease a ti it i u i e odels of SLE. MRA is a hu a ized o o lo al a ti od agai st the hu a ILe epto . Data f o li i al t ials i patie ts ith heu atoid a th itis suggest that MRA a e a effe ti e a d elati el safe age t to lo k the effe t of IL-.Mild a d t a sie t t a sa i itis, leu opoe ia a d dia hoea e e o se ed i the t eat e t g oup. He e, its ole ould possi l e e te ded to the t eat e t of SLE. A ope la el, dose-es alati g, Phase I stud of MRA i patie ts ith ode atel a ti e SLE is u e tl u de a to add ess its safet a d effi a .
. . I terfero -alfa IFN alfa a tago is
Re e t e ide e suggests that IFN-alfa a pla a ole i u i e lupus odels a d hu a SLE. The li i al o se atio that so e patie ts ith alig a o hepatitis C t eated ith IFN alfa de eloped autoi u e o ditio s su h as SLE led to a e a ea of esea h of IFN alfa a tago is as a pote tial ta get i SLE the ap . IFN alfa has u e ous iologi al a ti ities. It e ha ed T-ell a ti atio , diffe e tiatio a d toki e p odu tio IL hi h i tu a ti ates B ells a d autoA p odu tio th ough a a iet of e ha is s. Data f o u i e lupus odels le ds fu the suppo t to this o se atio . IFN/ etaR k o k out NZB/W F i e de o st ated sig ifi a t i p o e e t i se ologi al a d li i al a ifestatio s of SLE. Theo eti all , the e a e u e ous pote tial le els at hi h IFN-alfa a tago is a e ta geted ut se e al uestio s eed to e a s e ed su h as the possi le diffe e tial egulatio of INF alfa, the ole of IFN-alfa su t pes i SLE, the o e of o p o isi g a tii al i u e espo ses.
. . TNF alfa i hi itio
The e a t ole of TNF alfa i the pathoge i path a of SLE e ai s u lea . TNF lo kade i patie ts ith RA o C oh s disease has led to the de elop e t of lupus-like ill ess, de elop e t of a ti u lea a d a ti-ds DNA A s although i a ia l IgM, ot IgG i so e patie ts. O the o t a , t eat e t of u i e lupus ith a ti TNF the ap esulted i the apeuti e efit a d the p eli i a esults of a e e t ope pilot stud of si ef a to SLE patie ts fou ith eph itis, th ee ith a th itis e e gi e fou doses of IV I fli i a at g ea h, sho ed a % edu tio i p otei u ia at the e d of the follo -up pe iod as ell as e issio of a th itis a d disease a ti it , despite the e pe ted ise i a ti-dsDNA A s. It is ote o th ho e e that th ee out of the si patie ts de eloped u i a t a t i fe tio s, o pli ated E. oli a te ae ia i o e patie t. A plausi le e pla atio a e that a su set of SLE patie ts e ists i hi h TNF o e a ti it is p e-e i e t a d he e espo d to TNF lo kade. At p ese t ho e e , the e a e i suffi ie t data to e o e d idesp ead use of su h age ts i SLE.
. Ge e therapy P e li i al studies ha e p o ided p oof of o ept that ge e the ap i SLE is feasi le a d effe ti e. Su essful effo ts i lude ge e o st u ts that alte the e p essio of toki es ia i. . i je tio of aked DNA e odi g toki es o ade o i al ediated ge e t a sfe to CTLA -Ig i to u i e lupus odels ith esulta t li i al i p o e e t. Othe effo t a i lude ge e odified ge e t a sfe su h as autologous B ells t a sfe ted ith tole age i o st u ts o T ells i hi h spe ifi ole ula a e atio s ha e ee o e ted. Tu o e osis fa to alfa lo kade i s ste i lupus e the atosus: a ope -la el stud . A th itis Rheu ; :
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